Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Akebia Therapeutics Inc AKBA

Healthcare Biotechnology
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients... see more

Current News (NDAQ:AKBA)

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

GlobeNewswire 13 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 13 days ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire February 26, 2026

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

GlobeNewswire February 19, 2026

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire February 4, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2026

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

GlobeNewswire January 12, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

GlobeNewswire January 6, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2026
View More News ››

Opinion & Analysis (NDAQ:AKBA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:AKBA)

AKBA ....And that...Ladies & Gentleman.....is why I seldom

hold a position thru ER reporting !!!! Enuf said....Small position after the dust settled  Cheers
Iseneschal - March 9, 2023

AKBA.....ER before the open today

No position
Iseneschal - March 9, 2023

$AKBA AKEBIA SCORES ANOTHER POTENTIAL WIN IN KIDNEY DISEASE!

AKEBIA SCORES ANOTHER POTENTIAL WIN IN KIDNEY DISEASE! https://www.aviseanalytics.com/akebia-scores-another-potential-win-in-kidney...
AviseAnalytics - June 4, 2021

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

it's a buy today for me

this is a turnaround story with the bottom is past,so glta.
coolfooldumbguy - March 12, 2019
View more Bullboard ››

TomaGold Corp.

TomaGold Corp.

TomaGold Corporation, together with its subsidiaries, engages in the acquisition, exploration, assessment, and development of ...
View More »

Podcasts